2025

• Chung, J. *, Vallurupalli, M.*, Noel, S., Schor, G., Liu, Y., Nobrega, C., Perera, J. J., Wrona, E., Hu, M., Lin, Y., Wu, D. W., Saberi, M., Scapozza, I., Cruickshank, A., Woods, E. C., Chuong, C. L., Birocchi, F., Kammula, A. V., Avila, O. I., Kocak, M., Doench, J. G., Procter, D., Thornton, L., Brunner, A. M., Winer, E., DeAngelo, D. J., Garcia, J. S., Stone, R. M., Jenkins, R. W., Maus, M. V., Graubert, T. A., Yates, K. B., Golub, T. R.†, & Manguso, R. T.† (2025). Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosis. bioRxiv. 2025.05.05.652090.

2024

• Tsao, H. W.*, Anderson, S.*, Finn, K. J.*, Perera, J. J., Pass, L. F., Schneider, E. M., Jiang, A., Fetterman, R., Chuong, C. L., Kozuma, K., Stickler, M. M., Creixell, M., Klaeger, S., Phulphagar, K. M., Rachimi, S., Verzani, E. K., Olsson, N., Dubrot, J., Pech, M. F., Silkworth, W., Harding, F.†, Yates, K.B.†, Manguso, R. T.† (2024). Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. Immunity, 57(12), 2863–2878.e12. PMID: 39561763

2022

• Al-Kharboosh, R*., Perera, J. J.*, Bechtle, A., Bu, G., & Quinones-Hinojosa, A. (2022). Emerging point-of-care autologous cellular therapy using adipose-derived stromal vascular fraction for neurodegenerative diseases. Clinical and Translational Medicine, 12(12), e1093. PMCID: PMC9736801
• Tomaszewski, W. H.*, Waibl-Polania, J., Chakraborty, M., Perera, J., Ratiu, J., Miggelbrink, A., McDonnell, D. P., Khasraw, M., Ashley, D. M., Fecci, P. E., Racioppi, L., Sanchez-Perez, L., Gunn, M. D., & Sampson, J. H.† (2022). Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma. Nature Communications, 13(1), 6483. PMCID: PMC9617949

* denotes co-first authors.

† denotes co-corresponding authors.